APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioids Drug

Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are chemically related and interact with opioid receptors on nerve cells in the body and brain.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are chemically related and interact with opioid receptors on nerve cells in the body and brain.

Selected research

Market Outlook & Growth Opportunities

Global Opioids Drug Market Outlook and Growth Opportunities 2026

21 December 2025198 pages

Choose your research edition.

Industry ResearchOpioids Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioids Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Opioids Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioids Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioids Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are chemically related and interact with opioid receptors on nerve cells in the body and brain.

Global Opioids Drug main players are Purdue Pharma, Teva, Pfizer, Hikma, etc. Global top four manufacturers hold a share over 40%. North America is the largest market, with a share nearly 70%.

This report provides an overview of the global Opioids Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Opioids Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioids Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioids Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioids Drug Segment by Company

Teva

Purdue Pharma

Mallinckrodt

Amneal Pharma

Collegium

J&J

Endo

Pfizer

INSYS

Mylan

Hikma

Egalet

Opioids Drug Segment by Type

Oxycodone

Hydromorphone

Codeine

Fentanyl

Opioids Drug Segment by Application

Pain Relief

Anesthesia

Others

Opioids Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Opioids Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Opioids Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioids Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Opioids Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioids Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioids Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioids Drug industry.

Chapter 3: Detailed analysis of Opioids Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Opioids Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Opioids Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioids Drug Industry Trends Table 2. Opioids Drug Industry Drivers Table 3. Opioids Drug Industry Opportunities and Challenges Table 4. Opioids Drug Industry Restraints Table 5. Global Opioids Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioids Drug Revenue Share by Company (2021-2026) Table 7. Global Opioids Drug Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Opioids Drug Sales Volume Share by Company (2021-2026) Table 9. Global Opioids Drug Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Opioids Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Opioids Drug Key Company Manufacturing Base & Headquarters Table 12. Global Opioids Drug Company, Product Type & Application Table 13. Global Opioids Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioids Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oxycodone Table 18. Significant Companies of Hydromorphone Table 19. Significant Companies of Codeine Table 20. Significant Companies of Fentanyl Table 21. Global Opioids Drug Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 22. Global Opioids Drug Sales Volume by Type (2021-2026) & (M Units) Table 23. Global Opioids Drug Sales Volume by Type (2027-2032) & (M Units) Table 24. Global Opioids Drug Sales Volume Share by Type (2021-2026) Table 25. Global Opioids Drug Sales Volume Share by Type (2027-2032) Table 26. Global Opioids Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Opioids Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Opioids Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Opioids Drug Sales Value Share by Type (2021-2026) Table 30. Global Opioids Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Pain Relief Table 32. Significant Companies of Anesthesia Table 33. Significant Companies of Others Table 34. Global Opioids Drug Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 35. Global Opioids Drug Sales Volume by Application (2021-2026) & (M Units) Table 36. Global Opioids Drug Sales Volume by Application (2027-2032) & (M Units) Table 37. Global Opioids Drug Sales Volume Share by Application (2021-2026) Table 38. Global Opioids Drug Sales Volume Share by Application (2027-2032) Table 39. Global Opioids Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Opioids Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Opioids Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Opioids Drug Sales Value Share by Application (2021-2026) Table 43. Global Opioids Drug Sales Value Share by Application (2027-2032) Table 44. Global Opioids Drug Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 45. Global Opioids Drug Sales by Region (2021-2026) & (M Units) Table 46. Global Opioids Drug Sales Market Share by Region (2021-2026) Table 47. Global Opioids Drug Sales by Region (2027-2032) & (M Units) Table 48. Global Opioids Drug Sales Market Share by Region (2027-2032) Table 49. Global Opioids Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Opioids Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Opioids Drug Sales Value Share by Region (2021-2026) Table 52. Global Opioids Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Opioids Drug Sales Value Share by Region (2027-2032) Table 54. Global Opioids Drug Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Opioids Drug Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Opioids Drug Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 57. Global Opioids Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Opioids Drug Sales by Country (2021-2026) & (M Units) Table 59. Global Opioids Drug Sales Market Share by Country (2021-2026) Table 60. Global Opioids Drug Sales by Country (2027-2032) & (M Units) Table 61. Global Opioids Drug Sales Market Share by Country (2027-2032) Table 62. Global Opioids Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Opioids Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Opioids Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Opioids Drug Sales Value Market Share by Country (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. Teva Opioids Drug Product Portfolio Table 70. Teva Recent Development Table 71. Purdue Pharma Company Information Table 72. Purdue Pharma Business Overview Table 73. Purdue Pharma Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Purdue Pharma Opioids Drug Product Portfolio Table 75. Purdue Pharma Recent Development Table 76. Mallinckrodt Company Information Table 77. Mallinckrodt Business Overview Table 78. Mallinckrodt Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Mallinckrodt Opioids Drug Product Portfolio Table 80. Mallinckrodt Recent Development Table 81. Amneal Pharma Company Information Table 82. Amneal Pharma Business Overview Table 83. Amneal Pharma Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Amneal Pharma Opioids Drug Product Portfolio Table 85. Amneal Pharma Recent Development Table 86. Collegium Company Information Table 87. Collegium Business Overview Table 88. Collegium Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Collegium Opioids Drug Product Portfolio Table 90. Collegium Recent Development Table 91. J&J Company Information Table 92. J&J Business Overview Table 93. J&J Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. J&J Opioids Drug Product Portfolio Table 95. J&J Recent Development Table 96. Endo Company Information Table 97. Endo Business Overview Table 98. Endo Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Endo Opioids Drug Product Portfolio Table 100. Endo Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Opioids Drug Product Portfolio Table 105. Pfizer Recent Development Table 106. INSYS Company Information Table 107. INSYS Business Overview Table 108. INSYS Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. INSYS Opioids Drug Product Portfolio Table 110. INSYS Recent Development Table 111. Mylan Company Information Table 112. Mylan Business Overview Table 113. Mylan Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Mylan Opioids Drug Product Portfolio Table 115. Mylan Recent Development Table 116. Hikma Company Information Table 117. Hikma Business Overview Table 118. Hikma Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Hikma Opioids Drug Product Portfolio Table 120. Hikma Recent Development Table 121. Egalet Company Information Table 122. Egalet Business Overview Table 123. Egalet Opioids Drug Sales (M Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. Egalet Opioids Drug Product Portfolio Table 125. Egalet Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Opioids Drug Distributors List Table 129. Opioids Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Opioids Drug Product Image Figure 2. Global Opioids Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Opioids Drug Sales (2021-2032) & (M Units) Figure 5. Global Opioids Drug Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Opioids Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oxycodone Image Figure 10. Hydromorphone Image Figure 11. Codeine Image Figure 12. Fentanyl Image Figure 13. Global Opioids Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 14. Global Opioids Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Opioids Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Opioids Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Opioids Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Opioids Drug Sales Value Share by Type (2021-2032) Figure 19. Pain Relief Image Figure 20. Anesthesia Image Figure 21. Others Image Figure 22. Global Opioids Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 23. Global Opioids Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Opioids Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Opioids Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Opioids Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Opioids Drug Sales Value Share by Application (2021-2032) Figure 28. Global Opioids Drug Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 29. Global Opioids Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Opioids Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Opioids Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Opioids Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Opioids Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Opioids Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Opioids Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Opioids Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Opioids Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Opioids Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Opioids Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Opioids Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Opioids Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Opioids Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Oxycodone
  • Hydromorphone
  • Codeine
  • Fentanyl
Applications
  • Pain Relief
  • Anesthesia
  • Others
Companies covered
  • Teva
  • Purdue Pharma
  • Mallinckrodt
  • Amneal Pharma
  • Collegium
  • J&J
  • Endo
  • Pfizer
  • INSYS
  • Mylan
  • Hikma
  • Egalet

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioids Drug Sales Value (2021-2032)
  4. 1.2.2 Global Opioids Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Opioids Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Opioids Drug Market Dynamics
  1. 2.1 Opioids Drug Industry Trends
  2. 2.2 Opioids Drug Industry Drivers
  3. 2.3 Opioids Drug Industry Opportunities and Challenges
  4. 2.4 Opioids Drug Industry Restraints
3 Opioids Drug Market by Company
  1. 3.1 Global Opioids Drug Company Revenue Ranking in 2025
  2. 3.2 Global Opioids Drug Revenue by Company (2021-2026)
  3. 3.3 Global Opioids Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Opioids Drug Average Price by Company (2021-2026)
  5. 3.5 Global Opioids Drug Company Ranking (2024-2026)
  6. 3.6 Global Opioids Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Opioids Drug Company Product Type and Application
  8. 3.8 Global Opioids Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Opioids Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Opioids Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Opioids Drug Market by Type
  1. 4.1 Opioids Drug Type Introduction
  2. 4.1.1 Oxycodone
  3. 4.1.2 Hydromorphone
  4. 4.1.3 Codeine
  5. 4.1.4 Fentanyl
  6. 4.2 Global Opioids Drug Sales Volume by Type
  7. 4.2.1 Global Opioids Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioids Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Opioids Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Opioids Drug Sales Value by Type
  11. 4.3.1 Global Opioids Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Opioids Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Opioids Drug Sales Value Share by Type (2021-2032)
5 Opioids Drug Market by Application
  1. 5.1 Opioids Drug Application Introduction
  2. 5.1.1 Pain Relief
  3. 5.1.2 Anesthesia
  4. 5.1.3 Others
  5. 5.2 Global Opioids Drug Sales Volume by Application
  6. 5.2.1 Global Opioids Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioids Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Opioids Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Opioids Drug Sales Value by Application
  10. 5.3.1 Global Opioids Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioids Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Opioids Drug Sales Value Share by Application (2021-2032)
6 Opioids Drug Regional Sales and Value Analysis
  1. 6.1 Global Opioids Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioids Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Opioids Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Opioids Drug Sales by Region (2027-2032)
  5. 6.3 Global Opioids Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Opioids Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Opioids Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Opioids Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Opioids Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Opioids Drug Sales Value (2021-2032)
  12. 6.6.2 North America Opioids Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Opioids Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Opioids Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Opioids Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Opioids Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Opioids Drug Sales Value (2021-2032)
  21. 6.9.2 South America Opioids Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Opioids Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Opioids Drug Sales Value Share by Country, 2025 VS 2032
7 Opioids Drug Country-level Sales and Value Analysis
  1. 7.1 Global Opioids Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioids Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Opioids Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Opioids Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Opioids Drug Sales by Country (2027-2032)
  6. 7.4 Global Opioids Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Opioids Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Opioids Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Opioids Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Opioids Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Opioids Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Opioids Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Opioids Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Opioids Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Opioids Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Opioids Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Opioids Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Opioids Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Opioids Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Opioids Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Opioids Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Opioids Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Opioids Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Opioids Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Opioids Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Opioids Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Opioids Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Opioids Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Opioids Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Opioids Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Opioids Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Opioids Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Opioids Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Opioids Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Opioids Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Opioids Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Opioids Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Opioids Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Opioids Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Opioids Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Opioids Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Opioids Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Opioids Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Opioids Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Opioids Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Opioids Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Opioids Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Opioids Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Opioids Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Opioids Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Opioids Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Opioids Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Opioids Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Opioids Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Opioids Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Opioids Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Opioids Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Opioids Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Opioids Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Opioids Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Opioids Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Opioids Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Opioids Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Opioids Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Opioids Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Opioids Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Opioids Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Opioids Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Opioids Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Opioids Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Opioids Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Opioids Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Opioids Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Opioids Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Opioids Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Opioids Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Opioids Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Opioids Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Opioids Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Opioids Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Opioids Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Opioids Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Opioids Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Opioids Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Opioids Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Opioids Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Opioids Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Opioids Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Opioids Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Opioids Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Opioids Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Opioids Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Opioids Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Opioids Drug Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Purdue Pharma
  8. 8.2.1 Purdue Pharma Company Information
  9. 8.2.2 Purdue Pharma Business Overview
  10. 8.2.3 Purdue Pharma Opioids Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Purdue Pharma Opioids Drug Product Portfolio
  12. 8.2.5 Purdue Pharma Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Opioids Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Opioids Drug Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Amneal Pharma
  20. 8.4.1 Amneal Pharma Company Information
  21. 8.4.2 Amneal Pharma Business Overview
  22. 8.4.3 Amneal Pharma Opioids Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Amneal Pharma Opioids Drug Product Portfolio
  24. 8.4.5 Amneal Pharma Recent Developments
  25. 8.5 Collegium
  26. 8.5.1 Collegium Company Information
  27. 8.5.2 Collegium Business Overview
  28. 8.5.3 Collegium Opioids Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Collegium Opioids Drug Product Portfolio
  30. 8.5.5 Collegium Recent Developments
  31. 8.6 J&J
  32. 8.6.1 J&J Company Information
  33. 8.6.2 J&J Business Overview
  34. 8.6.3 J&J Opioids Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 J&J Opioids Drug Product Portfolio
  36. 8.6.5 J&J Recent Developments
  37. 8.7 Endo
  38. 8.7.1 Endo Company Information
  39. 8.7.2 Endo Business Overview
  40. 8.7.3 Endo Opioids Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Endo Opioids Drug Product Portfolio
  42. 8.7.5 Endo Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Opioids Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Opioids Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 INSYS
  50. 8.9.1 INSYS Company Information
  51. 8.9.2 INSYS Business Overview
  52. 8.9.3 INSYS Opioids Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 INSYS Opioids Drug Product Portfolio
  54. 8.9.5 INSYS Recent Developments
  55. 8.10 Mylan
  56. 8.10.1 Mylan Company Information
  57. 8.10.2 Mylan Business Overview
  58. 8.10.3 Mylan Opioids Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mylan Opioids Drug Product Portfolio
  60. 8.10.5 Mylan Recent Developments
  61. 8.11 Hikma
  62. 8.11.1 Hikma Company Information
  63. 8.11.2 Hikma Business Overview
  64. 8.11.3 Hikma Opioids Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hikma Opioids Drug Product Portfolio
  66. 8.11.5 Hikma Recent Developments
  67. 8.12 Egalet
  68. 8.12.1 Egalet Company Information
  69. 8.12.2 Egalet Business Overview
  70. 8.12.3 Egalet Opioids Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Egalet Opioids Drug Product Portfolio
  72. 8.12.5 Egalet Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioids Drug Value Chain Analysis
  2. 9.1.1 Opioids Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioids Drug Sales Mode & Process
  6. 9.2 Opioids Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioids Drug Distributors
  9. 9.2.3 Opioids Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst